Natural Human Interferon (Alpha-n3) is Active Against Both Wild-Type and Oseltamivir Resistant Avian-Origin Influenza A (H7N9) Virus
12 sept. 2013 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that at the 53rd annual meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy...
Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena
12 sept. 2013 07h45 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Chairman and CEO, William A. Carter, M.D. of Hemispherx Biopharma (NYSE MKT:HEB) announced at the Rodman and Renshaw Conference in New York City, NY on...
Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
12 sept. 2013 07h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 12, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) announced that at the Options for the Control of Influenza VIII Conference in Cape Town, South Africa held...
Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Potentially Reduce Pandemic Influenza Spread
04 sept. 2013 08h24 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT: HEB) announced that one of its advanced stage biological products, Alferon N Injection®, will be featured as...
Hemispherx Biopharma to Present at the 15th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
03 sept. 2013 16h05 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB), today announced it will be featured as a presenting company at the 15th Annual Rodman & Renshaw Global...
Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat
26 août 2013 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 26, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced that at the 2nd International Conference on Biodefense and Natural Disasters meeting in Orlando, FL on August...
Director of the U.S. Department of Homeland Security Center of Excellence for Emerging and Zoonotic Animal Diseases (CEEZAD), Professor J. Richt, DVM, Ph.D., to Present Programs to Reduce - Influenza Spread
20 août 2013 11h21 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 20, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that one of its advanced stage biological products, Alferon N®, will be featured as part of a new...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended June 30, 2013
09 août 2013 16h23 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 9, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE:HEB) announced its financial results for the three months ended June 30, 2013. The net loss (including non-cash effects) was...
Hemispherx Biopharma Appoints Peter W. Rodino III, Esq. to the Board of Directors and to Serve as Chairman of the Company's Audit Committee
29 juil. 2013 08h00 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 29, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that effective July 23, 2013, the Board of Directors of Hemispherx...
Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2013
08 mai 2013 15h53 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, May 8, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced its financial results for the three months ended March 31, 2013. The net loss (including non-cash effects)...